SOAT1 and leukemia: Since JAK2 mutations and dysregulated JAK-STAT signaling often contribute to leukemia cell survival, the use of JAK2 inhibitors in combination with conventional chemotherapy can sensitize leukemia cells to chemotherapeutic agents.